Convenience, efficacy, safety, and durability of INSTI-based antiretroviral therapies: evidence from the Italian MaSTER cohort
ConclusionOne-third of the population experienced an interruption of any drugs included in INSTI therapy in this study. The most frequent reason for interruption was safety concerns which accounted for one-fifth of interruptions among the full study population, mainly switched to DTG. The hazard for interruption was higher for low baseline CD4 + T-cell counts, higher baseline HIV-RNA, non-Italian nationality, older age, PWID and possible co-infections with hepatitis viruses. The risk ratio was higher for past history of cART use compared to persons who were cART naive, use of regimens containing 3 drugs compared to re...
Source: European Journal of Medical Research - August 18, 2023 Category: Research Source Type: research
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report
CONCLUSION: The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.PMID:37568163 | DOI:10.1186/s12981-023-00551-x (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - August 11, 2023 Category: Infectious Diseases Authors: Thamer A Almangour Preston T Skersick Amanda Corbett Jo E Rodgers Patricia P Chang Claire E Farel Source Type: research
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report
CONCLUSION: The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.PMID:37568163 | PMC:PMC10422718 | DOI:10.1186/s12981-023-00551-x (Source: Cell Research)
Source: Cell Research - August 11, 2023 Category: Cytology Authors: Thamer A Almangour Preston T Skersick Amanda Corbett Jo E Rodgers Patricia P Chang Claire E Farel Source Type: research
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report
CONCLUSION: The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.PMID:37568163 | PMC:PMC10422718 | DOI:10.1186/s12981-023-00551-x (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - August 11, 2023 Category: Infectious Diseases Authors: Thamer A Almangour Preston T Skersick Amanda Corbett Jo E Rodgers Patricia P Chang Claire E Farel Source Type: research
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report
CONCLUSION: The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.PMID:37568163 | PMC:PMC10422718 | DOI:10.1186/s12981-023-00551-x (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - August 11, 2023 Category: Infectious Diseases Authors: Thamer A Almangour Preston T Skersick Amanda Corbett Jo E Rodgers Patricia P Chang Claire E Farel Source Type: research
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report
CONCLUSION: The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.PMID:37568163 | PMC:PMC10422718 | DOI:10.1186/s12981-023-00551-x (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - August 11, 2023 Category: Infectious Diseases Authors: Thamer A Almangour Preston T Skersick Amanda Corbett Jo E Rodgers Patricia P Chang Claire E Farel Source Type: research
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report
CONCLUSION: The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.PMID:37568163 | PMC:PMC10422718 | DOI:10.1186/s12981-023-00551-x (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - August 11, 2023 Category: Infectious Diseases Authors: Thamer A Almangour Preston T Skersick Amanda Corbett Jo E Rodgers Patricia P Chang Claire E Farel Source Type: research
Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report
CONCLUSION: The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.PMID:37568163 | PMC:PMC10422718 | DOI:10.1186/s12981-023-00551-x (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - August 11, 2023 Category: Infectious Diseases Authors: Thamer A Almangour Preston T Skersick Amanda Corbett Jo E Rodgers Patricia P Chang Claire E Farel Source Type: research
Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review
ConclusionExposure to DRV increases modestly with age, while exposure to BIC, DOR and RAL appears to be unaffected by age. As the available evidence to confirm a potential effect of aging on ARV pharmacokinetics is limited, further studies are necessary. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - August 10, 2023 Category: Drugs & Pharmacology Source Type: research
Endothelial Glycocalyx Integrity in Treatment-Na ïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation
This study is the first to report the benefit of antiretroviral treatment on EG improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH.PMID:37515191 | PMC:PMC10383742 | DOI:10.3390/v15071505 (Source: Atherosclerosis)
Source: Atherosclerosis - July 29, 2023 Category: Cardiology Authors: Paraskevi C Fragkou Ignatios Ikonomidis Dimitrios Benas Dimitra Kavatha Charalampos D Moschopoulos Konstantinos Protopapas Gavriella Kostelli John Thymis Dionysia Mpirmpa Irene Galani Maria Tsakona Chrysanthi Oikonomopoulou George Theocharous Vassilis G G Source Type: research
Viruses, Vol. 15, Pages 1505: Endothelial Glycocalyx Integrity in Treatment-Na & iuml;ve People Living with HIV before and One Year after Antiretroviral Treatment Initiation
This study is the first to report the benefit of antiretroviral treatment on EG improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH. (Source: Viruses)
Source: Viruses - July 5, 2023 Category: Virology Authors: Paraskevi C. Fragkou Ignatios Ikonomidis Dimitrios Benas Dimitra Kavatha Charalampos D. Moschopoulos Konstantinos Protopapas Gavriella Kostelli John Thymis Dionysia Mpirmpa Irene Galani Maria Tsakona Chrysanthi Oikonomopoulou George Theocharous Vassilis G Tags: Article Source Type: research
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients.MethodsReal-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naïve patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) ≥200 copies/mL at...
Source: Frontiers in cellular and infection microbiology - June 26, 2023 Category: Microbiology Source Type: research
Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV
AIDS Research and Human Retroviruses, Ahead of Print. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - June 20, 2023 Category: Infectious Diseases Authors: Cecile D. Lahiri C. Christina Mehta Craig Sykes Sheri D. Weiser Frank Palella Jordan E. Lake John W. Mellors Deborah Gustafson Audrey L. French Adaora A. Adimora Deborah Konkle-Parker Anjali Sharma Hector Bolivar Seble G. Kassaye Leah H. Rubin Jessica A. Source Type: research
Mechanistic Modeling of the Drug-Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?
This study aimed at developing physiologically based pharmacokinetic models to simulate the switch from efavirenz to dolutegravir in the late second and third trimester. To this end, the drug-drug interaction between efavirenz and the uridine 5'-diphospho-glucuronosyltransferase 1A1 substrates dolutegravir and raltegravir was first simulated in nonpregnant subjects. After successful validation, the physiologically based pharmacokinetic models were translated to pregnancy and dolutegravir pharmacokinetics following efavirenz discontinuation were predicted. Modeling results indicated that, at the end of the second trimester,...
Source: The Journal of Clinical Pharmacology - June 15, 2023 Category: Drugs & Pharmacology Authors: Andr é Dallmann John van den Anker Homa K Ahmadzia Natella Rakhmanina Source Type: research
